This proposal is a competing continuation of the NIH grant RO1 CA89225. The long term-goal of this project is to improve the therapeutic outcomes in cancer via enhanced drug delivery of chemotherapeutic agents to multidrug resistant (MDR) tumors. This goal is achieved by combining anti-cancer drugs and block copolymers of poly(ethylene oxide) and polypropylene oxide) (""""""""Pluronics""""""""). Previous studies have shown that Pluronics 1) inhibit ATPase activity of P-glycoprotein (Pgp) and 2) deplete ATP in MDR cells. The synergy between these two effects results in the chemosensitization of MDR tumors. The objective of this proposal is i) to elucidate the mechanisms of Pgp inhibition and ATP depletion by Pluronic in MDR cells;ii) to evaluate these mechanisms in vivo by examining whether Pluronic induces Pgp inhibition and ATP depletion in MDR tumors;and iii) to determine whether Pluronic can prevent the appearance of the MDR in tumors induced by drugs. This proposal will (1) determine how Pluronics interact with Pgp in the membranes of MDR cells using the fluorescence resonance energy transfer (FRET) and photosensitized labeling;(2) determine how Pluronics affect respiration in the mitochondria of MDR cells by characterizing the effects of Pluronics on the activities of the respiratory chain complexes and the mitochondria! H+-ATPase;(3) determine whether Pluronics (a) increase the uptake of a Pgp probe within tumors (using single-photon emission computerized tomography (A- SPECT)), and (b) inhibit the energy metabolism in tumors (using 31P-magnetic resonance spectroscopy (31P-MRS));and, finally, (4) determine whether Pluronics can prevent the development of the drug resistance in tumors induced by anti-cancer drugs, doxorubicin and paclitaxel. As a result, the critical knowledge will be acquired on the activities of a novel chemotherapeutic agent composition that has promise in improving treatment of cancer patents.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
Other Basic Sciences
Schools of Pharmacy
United States
Zip Code
Alakhova, Daria Y; Kabanov, Alexander V (2014) Pluronics and MDR reversal: an update. Mol Pharm 11:2566-78
Zhao, Yi; Alakhova, Daria Y; Kabanov, Alexander V (2013) Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 65:1763-83
Alakhova, Daria Y; Zhao, Yi; Li, Shu et al. (2013) Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One 8:e72238
Zhao, Yi; Alakhova, Daria Y; Kim, Jong Oh et al. (2013) A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release 168:61-9
Dogan, Aysegul; Yalvac, Mehmet E; Sahin, Fikrettin et al. (2012) Differentiation of human stem cells is promoted by amphiphilic pluronic block copolymers. Int J Nanomedicine 7:4849-60
Batrakova, Elena V; Gendelman, Howard E; Kabanov, Alexander V (2011) Cell-mediated drug delivery. Expert Opin Drug Deliv 8:415-33
Luxenhofer, Robert; Sahay, Gaurav; Schulz, Anita et al. (2011) Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles. J Control Release 153:73-82
Luxenhofer, Robert; Schulz, Anita; Roques, Caroline et al. (2010) Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials 31:4972-9
Sahay, Gaurav; Alakhova, Daria Y; Kabanov, Alexander V (2010) Endocytosis of nanomedicines. J Control Release 145:182-95
Batrakova, Elena V; Li, Shu; Brynskikh, Anna M et al. (2010) Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 143:290-301

Showing the most recent 10 out of 34 publications